Recent advances in pathogenesis and management of hypereosinophilic syndromes

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 59, Issue 7, 2004, Pages 673-689

  Roufosse, F ^a,b   Cogan, E ^a   Goldman, M ^a  

^a ERASME HOSPITAL   (Belgium)

^b NONE   (Belgium)

Author keywords

Imatinib; Interleukin 5; Lymphoma; Myeloproliferative

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; BUSULFAN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; FLUDARABINE; GLUCOCORTICOID; HYDROXYUREA; IMATINIB; INTERLEUKIN 5 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PREDNISONE; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE;

BONE MARROW TRANSPLANTATION; CELL INFILTRATION; CHEMOTHERAPY; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CYTOGENETICS; CYTOLOGY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; EOSINOPHIL; EOSINOPHILIC LEUKEMIA; FOLLOW UP; GENETIC ANALYSIS; HEMATOLOGIC DISEASE; HISTORY OF MEDICINE; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; IMMUNE SYSTEM; LABORATORY TEST; LYMPHOCYTE; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PATIENT; PATIENT CARE; PATIENT CODING; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; STEM CELL TRANSPLANTATION; TOXICITY; TREATMENT INDICATION;

HUMANS; HYPEREOSINOPHILIC SYNDROME; LYMPHOCYTOSIS; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; T-LYMPHOCYTES;

EID: 3042742422     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2004.00465.x     Document Type: Review

References (73)

1. HARDY WR, ANDERSON RE. The hypereosinophilic syndromes. Ann Intern Med 1968;68:1220-1229.
2. CHUSID MJ, DALE DC, WEST BC, WOLFF SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54:1-27.
3. WELLER PF, BUBLEY GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759-2779.
4. FAUCI AS, HARLEY JB, ROBERTS WC, FERRANS VJ, GRALNICK HR, BJORNSON BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982;97:78-92.
5. BAIN BJ. Hypereosinophilia. Curr Opin Hematol 2000;7:21-25.
6. WARDLAW AJ. Eosinophils in the 1990s: new perspectives on their role in health and disease. Postgrad Med J. 1994;70:536-552.
7. VOWELS BR, CASSIN M, VONDERHEID EC, ROOK AH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992;99:90-94.
8. WATANABE M, ONO K, OZEKI Y, TANAKA S, AIDA S, OKUNO Y. Production of granulocyte-rnacrophage colony-stimulating factor in a patient with metastatic chest wall large cell carcinoma. Jpn J Clin Oncol 1998;28:559-562.
9. SANDERSON CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79:3101-3109.
10. ROMAGNANI S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996;80:225-235.
11. FLAUM MA, SCHOOLEY RT, FAUCI AS, GRALNICK HR. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood 1981;58: 1012-1020.
12. SCHOOLEY RT, FLAUM MA, GRALNICK HR, FAUCI AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 1981;58:1021-1026.
13. KEENE P, MENDELOW B, PINTO MR, BEZWODA W, MACDOUGALL L, FALKSON G et al. Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association. Br J Haematol 1987;67:25-31.
14. LUPPI M, MARASCA R, MORSELLI M, BAROZZI P, TORELLI G. Clonal nature of hypereosinophilic syndrome. Blood 1994;84:349-350.
15. CHANO HW, LEONG KH, KOH DR, LEE SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 1999;93:1651-1657.
16. COOLS J, DEANGELO DJ, GOTLIB J, STOVER EH, LEGARE RD, CORTES J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214.
17. SAVAGE DG, ANTMAN KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-693.
18. KLION AD, NOEL P, AKIN C, LAW MA, GILLILAND DG, COLLS J et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101:4660-4666.
19. GRIFFIN JH, LEUNG J, BRUNER RJ, CALIGIURI MA, BRIESEWITZ R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003;100:7830-7835.
20. PARDANANI A, KETTERLING RP, BROCKMAN SR, FLYNN HC, PATERNOSTER SF, SHEARER BM et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood 2003;102: 3093-3096.
21. KLION AD, ROBYN JA, AKIN C, NOEL P, BROWN MR, LAW MA et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004;103:473-478.
22. BAIN BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol 2003;122:173-179.
23. APPERLEY JF, GARDEMBAS M, MELO JV, RUSSELL-JONES R, BAIN BJ, BAXTER EJ et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
24. VANDENBERGHE P, WLODARSKA I, MICHAUX L, ZACHEE P, BOOGAERTS M, VANSTRAELEN D et al. Clinical and molecular features of FIPL1-PDGFRA(+) chronic eosinophilic leukemias. Leukemia 2004;18:734-742.
25. RAGHAVACHAR A, FLEISCHER S, FRICKHOFEN N, HEIMPEL H, FLEISCHER B. T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. J Immunol 1987;139:3753-3758.
26. SCHREZENMEIER H, THOME SD, TEWALD F, FLEISCHER B, RAGHAVACHAR A. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome. Exp Hematol 1993;21:358-365.
27. COGAN E, SCHANDENE L, CRUSIAUX A, COCHAUX P, VELU T, GOLDMAN M. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994;330:535-538.
28. SIMON HU, PLOTZ SG, DUMMER R, BLASER K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999;341:1112-1120.
29. ROUFOSSE F, SCHANDENÉ L, SIBILLE C, WILLARD-GALLO K, KENNES B, EFIRA A et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000;109:540-548.
30. BRUGNONI D, AIRO P, ROSSI G, BETTINARDI A, SIMON HU, GARZA L et al. A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood 1996;87:1416-1422.
31. KITANO K, ICHIKAWA N, SHIMODAIRA S, ITO T, ISHIDA F, KIVOSAWA K. Eosinophilia associated with clonal T-cell proliferation. Leuk Lymphoma 1997;27:335-342.
32. BANK I, AMARIGLIO N, RESHEF A, HARDAN I, CONFINO Y, TRAU H et al. The hypereosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes. Leuk Lymphoma 2001;42:123-133.
33. ZENONE T, FELMAN P, MALCUS C, DURIEU I, DURAND DV. Indolent course of a patient with hypereosinophilic syndrome associated with clonal T-cell proliferation. Am J Med 1999;107: 509-511.
34. SUGIMOTO K, TAMAYOSE K, SASAKI M. DANBARA T, AIKAWA Y, OGAWA H et al. More than 13 years of hypereosinophila associated with clonal CD3-CD4+ lymphocytosis of TH2/TH0 type. Int J Hematol 2002;75:281-284.
35. ROUMIER AS, GRARDEL N, LAI JL, BECQUERIAUX I, GHOMARI K, DE LAVAREILLE A et al. Hypereosinophilia with abnormal T cells, trisomy 7 and elevated TARC serum level. Haematologica 2003;88:ECR24.
36. ROUFOSSE F, COGAN E, GOLDMAN M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003;54:169-184.
37. REINHOLD U, LIU L, SESTERHENN J, ABKEN H. CD7-negative T cells represent a separate differentiation pathway in a subset of post-thymic helper T cells. Immunology 1996;89:391-396.
38. GLEICH GJ, SCHROETER AL, MARCOUX JP, SACHS MI, O'CONNELL EJ, KOHLER PF. Episodic angioedema associated with eosinophilia. N Engl J Med 1984;310:1621-1626.
39. SIMON HU, YOUSEFI S, DOMMANN-SCHERRER CC, ZIMMERMANN DR, BAUER S, BARANDUN J et al. Expansion of cytokine-producing CD4-CD8-T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996;183:1071-1082.
40. SCHANDENÉ L, ROUFOSSE F, DE LAVAREILLE A, STORDEUR P, EFIRA A, KENNES B et al. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood 2000;96:4285-4292.
41. LUSSO P, MALNATI M, DE MARIA A, BALOTTA C, DEROCCO SE, MARKHAM PD et al. Productive infection of CD4+ and CD8+ mature human T cell populations and clones by human herpesvirus 6. Transcriptional down-regulation of CD3. J Immunol 1991;147:685-691.
42. DE WAAL MALEFYT R, YSSEL H, SPITS H, DE VRIES JE, SANCHO J, TERHORST C et al. Human T cell leukemia virus type I prevents cell surface expression of the T cell receptor through down-regulation of the CD3-gamma, -delta, -epsilon, and -zeta genes. J Immunol 1990;145: 2297-2303.
43. WILLARD-GALLO KE, VAN DE KEERE F, KETTMANN R. A specific defect in CD3 gamma-chain gene transcription results in loss of T-cell receptor/CD3 expression late after human immunodeficiency virus infection of a CD4+ T-cell line. Proc Natl Acad Sci USA 1990;87:6713-6717.
44. LUTON F, BUFERNE M, DAVOUST J, SCHMITT-VERHULST AM, BOYER C. Evidence for protein tyrosine kinase involvement in ligand-induced TCR/ CD3 internalization and surface redistribution. J Immunol 1994;153:63-72.
45. LEY SC, TAN KN, KUBO R, SY MS, TERHORST C. Surface expression of CD3 in the absence of T cell receptor (TcR): evidence for sorting of partial TcR/CD3 complexes in a post-endoplasmic reticulum compartment. Eur J Immunol 1989;19:2309-2317.
46. HUANG CS, GOMEZ GA, KOHNO SI, SOKAL JE, SANDBERG AA. Chromosomes and causation of human cancer and leukemia. XXXIV. A case of 'hypereosinophilic syndrome' with unusual cytogenetic findings in a chloroma, terminating in blastic transformation and CNS leukemia. Cancer 1979;44:1284-1289.
47. O'SHEA JJ, JAFFE ES, LANE HC, MACDERMOTT RP, FAUCI AS. Peripheral T cell lymphoma presenting as hypereosinophilia with vasculitis. Clinical, pathologic, and immunologic features. Am J Med 1987;82:539-545.
48. BAGOT M, BODEMER C, WECHSLER J, DIVINE M, HAIOUN C, CAPESIUS C et al. Non epidermotropic T lymphoma preceded for several years by hypereosinophilic syndrome. Ann Dermatol Venereol 1990;117:883-885.
49. BRUGNONI D, AIRO P, TOSONI C, TAGLIETTI M, LODI-RIZZINI F, CALZAVARA-PINTON P et al. CD3-CD4+ cells with a Th2-like pattern of cytokine production in the peripheral blood of a patient with cutaneous T cell lymphoma. Leukemia 1997;11:1983-1985.
50. KYOIZUMI S, AKIYAMA M, HIRAI Y, KUSUNOKI Y, TANABE K, UMEKI S. Spontaneous loss and alteration of antigen receptor expression in mature CD4+ T cells. J Exp Med 1990; 171:1981-1999.
51. SERKE S, VAN LESSEN A, HUMMEL M, SZCZEPEK A, HUHN D, STEIN H. Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma. Cytometry 2000;42:180-187.
52. ROUFOSSE F, SCHANDENÉ L, SIBILLE C, KENNES B, EFIRA A, COGAN E et al. T-cell receptor-independent activation of clonal Th2 cells associated with chronic hypereosinophilia. Blood 1999;94:994-1002.
53. LEPRETRE S, BUCHONNET G, STAMATOULLAS A, LENAIN P, DUVAL C, D'ANJOU J et al. Chromosome abnormalities in peripheral T-cell lymphoma. Cancer Genet Cytogenet 2000;117: 71-79.
54. THANGAVELU M, FINN WG, YELAVARTHI KK, ROENIGK HH, SAMUELSON E, PETERSON L et al. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sezary syndrome. Blood 1997;89:3371-3377.
55. COLLINS RD. Is clonality equivalent to malignancy: specifically, is immunoglobulin gene rearrangement diagnostic of malignant lymphoma? Hum Pathol 1997;28:757-759.
56. DE LAVAREILLE A, ROUFOSSE F, SCHMID-GRENDELMEIER P, SCHMID-GREDELMEIER P, ROUMIER AS, SCHANDENÉ L, COGAN E et al. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 2002;110:476-479.
57. PARDANANI A, REEDER T, PORRATA LF, LI CY, TAZELAAR HD, BAXTER EJ et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101:3391-3397.
58. LAMKHIOUED B, GOUNNI AS, ALDEBERT D, DELAPORTE E, PRIN L, CAPRON A et al. Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Ann NY Acad Sci 1996;796:203-208.
59. PLUMAS J, GRUART V, ALDEBERT D, TRUONG MJ, CAPRON M, CAPRON A et al. Human eosinophils from hypereosinophilic patients spontaneously express the p55 but not the p75 interleukin 2 receptor subunit. Eur J Immunol. 1991;21:1265-1270.
60. KAKINUMA T, NAKAMURA K, WAKUGAWA M, MITSUI H, TADA Y, SAEKI H et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001;107:535-541.
61. BUTTERFIELD JH, GLEICH GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994;121:648-653.
62. SCHALLER JL, BURKLAND GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 2001;3:9.
63. GLEICH GJ, LEIFERMAN KM, PARDANANI A, TEFFERI A, BUTTERFIELD JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359:1577-1578.
64. CORTES J, AULT P, KOLLER C, THOMAS D, FERRAJOLI A, WIERDA W et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophiHc syndrome. Blood 2003;101:4714-4716.
65. PITINI V, ARRIGO C, AZZARELLO D, LA GATTUTA G, AMATA C, RIGHI M et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003;102:3456-3457.
66. BRAUN CM, HUANG SK, BASHIAN GG, KAGEY-SOBOTKA A, LICHTENSTEIN LM, ESSAYAN DM. Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses. J Allergy Clin Immunol 1997;100:400-407.
67. PARRONCHI P, DE CARLI M, MANETTI R, SIMONELLI C, SAMPOGNARO S, PICCINNI MP et al. IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 1992;149:2977-2983.
68. SCHANDENÉ L, DEL PRETE GF, COGAN E, STORDEUR P, CRUSIAUX A, KENNES B et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest 1996;97:309-315.
69. WOERLY G, ROGER N, LOISEAU S, DOMBROWICZ D, CAPRON A, CAPRON M. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes. J Exp Med 1999;190:487-495.
70. AUBIN F, SALARD D, POUTHIER F, HERVÉ P, HUMBERT P. La photochimiothérapie extracorporelle. Méd/Sci 1999;15:983-989.
71. ADKINS JC, PETERS DH, MARKHAM A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997;53:1005-1037.
72. PLOTZ SG, SIMON HU, DARSOW U, SIMON D, VASSINA E, YOUSEFI S et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349:2334-2339.
73. GARRETT JK, JAMESON SC, THOMSON B, COLLINS MH, WAGONER LE, FREESE DK et al. Anti-interleukin-5 (mepolizumab) therapy for hyperreosinophilic syndromes. J Allergy Clin Immunol 2004;113:115-119